Given that RPS27L knockdown increases the sensitivity of lung cancer cells to MMC, and RPS27L expression is reduced in NSCLC tissues, our study suggests that ICL-inducing chemotherapeutic agents may have better therapeutic efficacy in the treatment of NSCLC patients with low RPS27L expression. The gene discussed is RPS27L; the disease is lung cancer.